[go: up one dir, main page]

MX2016017142A - Dispersion solida de allisartan isoproxilo y composicion farmaceutica que comprende la misma. - Google Patents

Dispersion solida de allisartan isoproxilo y composicion farmaceutica que comprende la misma.

Info

Publication number
MX2016017142A
MX2016017142A MX2016017142A MX2016017142A MX2016017142A MX 2016017142 A MX2016017142 A MX 2016017142A MX 2016017142 A MX2016017142 A MX 2016017142A MX 2016017142 A MX2016017142 A MX 2016017142A MX 2016017142 A MX2016017142 A MX 2016017142A
Authority
MX
Mexico
Prior art keywords
solid dispersion
allisartan isoproxil
pharmaceutical composition
same
isoproxil solid
Prior art date
Application number
MX2016017142A
Other languages
English (en)
Inventor
Shui Bu
Guanhao Ye
Original Assignee
Shenzhen Salubris Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Salubris Pharm Co Ltd filed Critical Shenzhen Salubris Pharm Co Ltd
Publication of MX2016017142A publication Critical patent/MX2016017142A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una dispersión sólida de Allisartan Isoproxilo, composición farmacéutica que lo comprende y uso del mismo. La dispersión sólida de Allisartan Isoproxilo consiste de Allisartan Isoproxilo y un material portador farmacéuticamente aceptable, el material portador comprende un portador solubilizante y un surfactante, la relación de masa del Allisartan Isoproxilo para el surfactante es 1:0.01-0.010.
MX2016017142A 2014-07-01 2015-06-30 Dispersion solida de allisartan isoproxilo y composicion farmaceutica que comprende la misma. MX2016017142A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201410310848 2014-07-01
PCT/CN2015/082994 WO2016000608A1 (zh) 2014-07-01 2015-06-30 一种阿利沙坦酯固体分散体及含有该固体分散体的药物组合物

Publications (1)

Publication Number Publication Date
MX2016017142A true MX2016017142A (es) 2017-07-28

Family

ID=55018454

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016017142A MX2016017142A (es) 2014-07-01 2015-06-30 Dispersion solida de allisartan isoproxilo y composicion farmaceutica que comprende la misma.

Country Status (10)

Country Link
US (1) US20170157095A1 (es)
EP (1) EP3165219A4 (es)
JP (1) JP6293315B2 (es)
KR (1) KR101895962B1 (es)
CN (1) CN105232489B (es)
CA (1) CA2949164A1 (es)
MX (1) MX2016017142A (es)
RU (1) RU2017102990A (es)
TW (1) TWI592154B (es)
WO (1) WO2016000608A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107441497A (zh) * 2016-05-31 2017-12-08 深圳信立泰药业股份有限公司 一种阿利沙坦酯固体分散体及其制备方法及含有该固体分散体的制剂
AU2019212828A1 (en) * 2018-01-29 2020-08-27 Mark Michael MENNING Process for creating solid dispersions
CN111297872B (zh) * 2020-03-02 2021-01-12 牡丹江医学院 一种治疗慢性萎缩性胃炎的药物及其制备方法
CN111419800B (zh) * 2020-04-23 2021-03-19 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 用于治疗红斑狼疮的药物制剂及其制备方法
CN112089699B (zh) * 2020-09-29 2022-01-28 广东逸舒制药股份有限公司 一种氯雷他定速缓释片及其制备工艺
CN119367359B (zh) * 2024-10-23 2025-10-17 济南舜景医药科技有限公司 一种阿利沙坦酯组合物及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1241566C (zh) * 2004-03-15 2006-02-15 深圳海王药业有限公司 西洛他唑固体分散体及其片剂制备方法
CN101214242A (zh) * 2007-01-05 2008-07-09 上海艾力斯医药科技有限公司 新的药用组合物
CN101066264A (zh) * 2007-06-12 2007-11-07 杨喜鸿 奥美沙坦酯的固体分散体及其制备方法和药物应用
CN101961306B (zh) * 2009-07-24 2011-11-09 北京化工大学 一种低熔点药物固体分散体的制备方法
CN102178642A (zh) * 2011-04-29 2011-09-14 苏州大学 一种替米沙坦固体分散体及其制备方法
CN102357078A (zh) * 2011-10-17 2012-02-22 苏州大学 一种缬沙坦固体分散体及其制备方法
KR101441450B1 (ko) * 2012-10-22 2014-09-24 충남대학교산학협력단 생체 이용률이 향상된 에프로살탄 고체 분산체, 이의 제조방법 및 용도
CN105078974A (zh) * 2014-05-23 2015-11-25 深圳信立泰药业股份有限公司 一种阿利沙坦酯固体分散体及药物组合物

Also Published As

Publication number Publication date
CA2949164A1 (en) 2016-01-07
KR101895962B1 (ko) 2018-10-18
TW201601719A (zh) 2016-01-16
CN105232489A (zh) 2016-01-13
CN105232489B (zh) 2019-06-11
US20170157095A1 (en) 2017-06-08
RU2017102990A3 (es) 2018-08-01
JP6293315B2 (ja) 2018-03-14
WO2016000608A1 (zh) 2016-01-07
EP3165219A1 (en) 2017-05-10
KR20170040795A (ko) 2017-04-13
EP3165219A4 (en) 2017-12-27
JP2017519789A (ja) 2017-07-20
TWI592154B (zh) 2017-07-21
RU2017102990A (ru) 2018-08-01

Similar Documents

Publication Publication Date Title
SG10201803042PA (en) Anti-tim-3 antibodies
MY191581A (en) Anti-pd-1 antibodies
EP4516319A3 (en) Subcutaneous formulations of anti-cd38 antibodies and their uses
MY191035A (en) Affinity-oligonucleotide conjugates and uses thereof
EP3615659A4 (en) COMPOSITIONS AND METHODS OF ENCAPSULATION AND SCALABLE DELIVERY OF AGROCHEMICALS
PH12017500555A1 (en) Modified phosphpors and compositions thereof
EP3129048A4 (en) Antibodies, pharmaceutical compositions and uses thereof
MX2016017142A (es) Dispersion solida de allisartan isoproxilo y composicion farmaceutica que comprende la misma.
SG10201902203VA (en) Eutectic formulations of cyclobenzaprine hydrochloride
PH12016501841A1 (en) Immunosuppressant formulation
MX2019002057A (es) Formas solidas de mesilato de cenicriviroc y procesos para elaborar formas sólidas de mesilato de cenicriviroc.
IL248785B (en) Antecedents of ]-n5,1-dimethyl3--oxo-(3,2-dihydro-h1-pyrazol-4-yl)]-methyl-isoxazole-3-carboxamide and pharmaceutical preparations including these antecedents
WO2017100107A3 (en) Co-agonists of the glucagon and glp-1 receptors
ZA201803476B (en) Anti-cd22 antibody-maytansine conjugates and methods of use thereof
PH12017500451A1 (en) Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl) oxy)-n, 2-dimethylbenzofuran -3- carboxamide
WO2017074798A3 (en) Long-acting co-agonists of the glucagon and glp-1 receptors
MX2016015261A (es) Dispersion solida de allisartan isoproxilo y su composicion.
IN2014CH00840A (es)
MY178960A (en) Hiv treatment formulation of atazanavir and cobicistat
GEP20196977B (en) Pharmaceutical formulations of vildagliptin
EP3239264A4 (en) Friction material composition, friction material using same, and friction member
PH12017502148A1 (en) Pharmaceutical compositions and use thereof
MX2020002793A (es) Composiciones de microesferas de gas encapsulado en lipidos y metodos relacionados.
MX2016013439A (es) Formas solidas de un compuesto farmaceuticamente activo.
IL257621B (en) A catechol derivative and a pharmaceutical preparation that includes it